Prognostic significance of initial tumor shrinkage in patients with stage III non-small cell lung cancer treated with durvalumab following chemoradiotherapy-Reference-Cited by-同舟云学术

Prognostic significance of initial tumor shrinkage in patients with stage III non-small cell lung cancer treated with durvalumab following chemoradiotherapy

Published:2023-11-30 Issue:2 Volume:29 Page:115-123
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Terashima Yuto^ORCID,Hakozaki Taiki^ORCID,Uehara Yuji^ORCID,Miyanaga Akihiko,Kasahara Kazuo^ORCID,Seike Masahiro,Hosomi Yukio^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-023-02436-5.pdf

Reference25 articles.

1. Antonia SJ et al (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379(24):2342–2350. https://doi.org/10.1056/nejmoa1809697

2. Faivre-Finn C et al (2021) Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC—an update from the PACIFIC trial. J Thorac Oncol 16(5):860–867. https://doi.org/10.1016/j.jtho.2020.12.015

3. Spigel DR et al (2022) Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol 40:1301–1311. https://doi.org/10.1200/JCO.21

4. Kartolo A, Shah H, Hopman W et al (2021) Consolidative durvalumab outcomes in stage III non-small cell lung cancer in a multi-centre study. Cancer Treat Res Commun. https://doi.org/10.1016/j.ctarc.2021.100496

5. Guberina M et al (2022) Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors. Immunotherapy 14(12):927–944. https://doi.org/10.2217/imt-2021-0341

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy revolutionizing brain metastatic cancer treatment: personalized strategies for transformative outcomes;Frontiers in Immunology;2024-07-29